The result suggested that changes in naive CD4 cell, particularly differences in T cell receptors and TLR signaling pathways, can determine the rate of disease progression in patients, which is critical for MS prognosis (Zastepa et al., 2014). This evidence concerns the gene CD4 and myeloid sarcoma.